Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Identifies Cancer Target Using In-house System

NEW YORK, Oct. 9 – Myriad Genetics of Salt Lake City said Tuesday it had discovered a drug target for treating cancer using its proteomics technology.

In a statement, Myriad said that the ProNet technology allowed the company to look at protein interactions involved in apoptosis and to apply the knowledge garnered to identifying a target for cancer.

“Pre-clinical studies have demonstrated strong anti-cancer activity without harming normal human cell survival,” the company said in a statement.

Last month the company said that using ProNet it had found a drug target for hepatitis C. Myriad has also used the technique in its efforts to find drug targets for HIV and hepatitis B.

ProNet uses yeast two-hybrid to identify protein-protein interactions and to find intracellular, secreted, and membrane proteins. Myriad said that its system has a false positive rate of less than one percent and higher throughput than other methods. 

Myriad, which is currently conducting tests on a prostate cancer drug and a colon cancer, said that it would now deploy its medicinal and organic chemistry capabilities to further develop anti-cancer compounds.  

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.